Pritesh R Patel
Overview
Explore the profile of Pritesh R Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
209
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel P, Modi K, Patel S
Environ Sci Pollut Res Int
. 2024 Dec;
32(2):693-724.
PMID: 39699791
The lower productivity of square pyramid solar still is the prime impediment to its worldwide applicability. In the present study, efforts have been made to improve the productivity of square...
2.
Mohyuddin G, Guadamuz J, Ascha M, Chiu B, Patel P, Sweiss K, et al.
Blood Adv
. 2024 Aug;
8(21):5539-5541.
PMID: 39207867
No abstract available.
3.
Nabulsi N, Sharp L, Sweiss K, Patel P, Calip G, Lee T
J Oncol Pharm Pract
. 2023 Nov;
30(8):1317-1329.
PMID: 37942515
Introduction: Treatment advances for hematologic malignancies (HM) have dramatically improved life expectancy, necessitating greater focus on long-term cancer pain management. This study explored real-world patterns of opioid use among patients...
4.
Nabulsi N, Nazari J, Lee T, Patel P, Sweiss K, Le T, et al.
J Cancer Surviv
. 2023 Apr;
18(4):1285-1296.
PMID: 37022642
Purpose: Opioids are essential for treating pain in hematologic malignancies (HM), yet are heavily stigmatized in the era of the opioid epidemic. Stigma and negative attitudes towards opioids may contribute...
5.
Zhou J, Sweiss K, Han J, Ko N, Patel P, Chiu B, et al.
JAMA Netw Open
. 2021 Jul;
4(7):e2118410.
PMID: 34313746
No abstract available.
6.
Zhou J, Sweiss K, Nutescu E, Han J, Patel P, Ko N, et al.
JCO Oncol Pract
. 2021 Jan;
17(3):e294-e312.
PMID: 33449809
Purpose: Intravenous (IV) bisphosphonates reduce the risk of skeletal-related events in patients with multiple myeloma (MM). However, data describing racial differences in IV bisphosphonate utilization outside of clinical trial settings...
7.
Han J, Holden C, Ahluwalia A, Molokie R, Gowhari M, Sweiss K, et al.
Br J Haematol
. 2020 Jul;
191(3):e70-e72.
PMID: 32693435
No abstract available.
8.
Nabulsi N, Alobaidi A, Talon B, Asfaw A, Zhou J, Sharp L, et al.
Cancer Causes Control
. 2020 May;
31(7):641-650.
PMID: 32356139
Purpose: Patient-reported outcomes such as self-reported health (SRH) are important in understanding quality cancer care, yet little is known about links between SRH and outcomes in older patients with multiple...
9.
Patel P, Senyuk V, Sweiss K, Calip G, Pan D, Rodriguez N, et al.
Biol Blood Marrow Transplant
. 2020 Mar;
26(7):1273-1279.
PMID: 32194286
High-dose melphalan (MEL) and autologous stem cell transplantation (ASCT) is the standard of care in the treatment of multiple myeloma (MM). Resistance to MEL has been linked to increased DNA...
10.
Calip G, Patel P, Sweiss K, Wu Z, Zhou J, Asfaw A, et al.
Int J Cancer
. 2020 Jan;
147(5):1300-1305.
PMID: 31997371
Several commonly used immune-suppressing biologic drugs target proteins and cytokines involved in myeloma pathogenesis. Our objective was to determine whether targeted biologic disease-modifying antirheumatic drugs (DMARDs) are associated with risk...